What modifications did apotex make to ruxolitinib's chemical structure?

What chemical changes did Apotex make to ruxolitinib?

The information provided does not include any details about modifications Apotex made to ruxolitinib’s chemical structure. Without the relevant patent, filing, or Apotex document (e.g., a specific application number, claim set, or comparison table), it’s not possible to say what structural changes were made.

Where to find the exact structural modifications (and what to look for)

To identify the exact chemical structure changes, you typically need one of the following:
- A patent publication from Apotex describing the “ruxolitinib” compound they made (or a “derivative” or “salt” form) with explicit chemical formulas and substituent changes.
- A drug label or regulatory submission that specifies which form is used (free base vs. a particular salt) and may reference structure/chemical naming.
- A prosecution history or claim chart that compares the Apotex structure to the reference compound.

In those sources, the modifications usually appear as differences in the named substituents, salt form, stereochemistry (if any), or protecting groups—often in claim language or in the examples section.

Can you share the document so I can extract the modifications?

If you paste the relevant text or provide the patent/publication number or link (or even the chemical name Apotex used), I can extract exactly what Apotex changed in the ruxolitinib structure and describe the modifications precisely.